Literature DB >> 15545982

Targeting oncogenes.

Laurie Goodman.   

Abstract

Mesh：

Substances：

Year:  2004        PMID： 15545982      PMCID： PMC525756          DOI： 10.1172/JCI23689

Source DB:  PubMed          Journal:  J Clin Invest        ISSN： 0021-9738            Impact factor:   14.808


× No keyword cloud information.
  5 in total

1.  Reversible tumorigenesis by MYC in hematopoietic lineages.

Authors:  D W Felsher; J M Bishop
Journal:  Mol Cell       Date:  1999-08       Impact factor: 17.970

2.  c-MYC induces mammary tumorigenesis by means of a preferred pathway involving spontaneous Kras2 mutations.

Authors:  C M D'Cruz; E J Gunther; R B Boxer; J L Hartman; L Sintasath; S E Moody; J D Cox; S I Ha; G K Belka; A Golant; R D Cardiff; L A Chodosh
Journal:  Nat Med       Date:  2001-02       Impact factor: 53.440

3.  MYC inactivation uncovers pluripotent differentiation and tumour dormancy in hepatocellular cancer.

Authors:  Catherine M Shachaf; Andrew M Kopelman; Constadina Arvanitis; Asa Karlsson; Shelly Beer; Stefanie Mandl; Michael H Bachmann; Alexander D Borowsky; Boris Ruebner; Robert D Cardiff; Qiwei Yang; J Michael Bishop; Christopher H Contag; Dean W Felsher
Journal:  Nature       Date:  2004-10-10       Impact factor: 49.962

4.  Sustained loss of a neoplastic phenotype by brief inactivation of MYC.

Authors:  Meenakshi Jain; Constadina Arvanitis; Kenneth Chu; William Dewey; Edith Leonhardt; Maxine Trinh; Christopher D Sundberg; J Michael Bishop; Dean W Felsher
Journal:  Science       Date:  2002-07-05       Impact factor: 47.728

5.  Genomically complex lymphomas undergo sustained tumor regression upon MYC inactivation unless they acquire novel chromosomal translocations.

Authors:  Asa Karlsson; Sylvie Giuriato; Flora Tang; Jingly Fung-Weier; Göran Levan; Dean W Felsher
Journal:  Blood       Date:  2002-11-27       Impact factor: 22.113
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.